Actuate Therapeutics

Historical price data

Actuate Therapeutics is a micro-cap, clinical-stage biotech focused on developing elraglusib, a selective GSK-3β inhibitor, for difficult-to-treat cancers. Its strategy leverages a dual mechanism of action—direct tumor cytotoxicity and immune modulation—to enhance the efficacy of chemotherapy and immunotherapy. The company has advanced elraglusib into multiple Phase 2 trials in pancreatic cancer, salivary gland carcinoma, and hematologic malignancies, positioning it as a high-risk, high-reward investment tied to clinical data readouts.

Platform centered on elraglusib, a novel small molecule inhibitor of GSK-3β designed to directly inhibit tumor growth pathways and modulate the tumor immune microenvironment to overcome therapy resistance.

Faces limited direct competition from other GSK-3β inhibitors in oncology but indirect competition from numerous companies developing targeted therapies and next-generation immunotherapies for the same hard-to-treat cancers. Differentiation hinges on proving elraglusib's unique dual mechanism of action.